Crispr Therapeutics AG (CRSP) AI Stock Analysis

• Market Cap: $4.79B
• Dividend Yield: N/A
• Average Volume (3M): 2.71M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.16
• Revenue Growth: -81.18%
• EPS Growth: -69.19%
• Country: US
• Employees: 393
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -2.40
• Shares Outstanding: 90,950,424
• 10 Day Avg. Volume: 1,678,681
• 30 Day Avg. Volume: 2,711,520
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.57
• Enterprise Value/Revenue: 72.96
• Enterprise Value/Gross Profit: -33.63
• Enterprise Value/Ebitda: -5.33
• 1Y Price Target: $71.29
• Price Target Upside: 35.17% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 17

• Rating: 46 Neutral
• Price Target: $52.00 ▼(-1.40% Downside)

Crispr Therapeutics AG's overall score reflects significant financial challenges and weak technical indicators, offset by positive corporate events. The company's strategic advancements in cardiovascular programs and governance improvements are promising, but financial and valuation concerns weigh heavily on the score.

Positive Factors

Clinical Trials

Impressive topline results for CTX310 demonstrated reductions of up to 82% in triglycerides, and 86% in LDL from baseline in high-risk patients.

Financial Performance

Casgevy sales reached $30.4mm, surpassing expectations and showing strong performance in the market.

Global Expansion

CRISPR Therapeutics has reached the target activation of 75 authorized treatment centers globally, which is expected to further catalyze growth.

Negative Factors

Earnings

CRISPR Therapeutics recorded a net loss of $2.38 per share, which was significantly wider than the prior estimate.

Pipeline Validation

Bears argue pipeline validation is needed to justify further upside, indicating skepticism about future performance.

R&D Spending

R&D spending was below expectations, which might raise concerns about future development progress.

Crispr Therapeutics AG Business Overview & Revenue Model

Company Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

How the Company Makes Money

Crispr Therapeutics generates revenue through a combination of product sales, research collaborations, and licensing agreements. The company is primarily focused on advancing its gene-editing therapies through clinical trials, which, upon successful commercialization, could lead to significant sales revenue. In addition, Crispr Therapeutics has established partnerships with major pharmaceutical companies, such as Vertex Pharmaceuticals, which contribute to its financial resources through upfront payments, milestone payments based on clinical and regulatory progress, and royalty payments on future sales of products developed through these collaborations. These collaborations not only provide funding but also enhance the company's capabilities in research and development, thus contributing to its potential earnings.

Crispr Therapeutics AG Financial Statement Overview

Summary

Crispr Therapeutics AG faces significant financial challenges, with negative profitability and cash flow metrics. Despite manageable leverage, the company struggles with generating positive returns and cash flows, likely due to high R&D costs typical in the biotechnology industry.

Income Statement

Crispr Therapeutics AG has experienced significant volatility in its revenue and profit margins. The TTM data shows a slight revenue growth, but the company is struggling with negative gross and net profit margins, indicating high costs relative to revenue. The EBIT and EBITDA margins are also negative, reflecting operational challenges. Despite a past year of strong revenue growth, recent trends show declining profitability.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio, suggesting manageable leverage. However, the return on equity is negative, indicating that the company is not generating profit from its equity base. The equity ratio is stable, reflecting a solid asset base, but the negative ROE highlights profitability issues.

Cash Flow

Crispr Therapeutics AG's cash flow statement reveals negative operating and free cash flows, which are concerning for sustainability. The free cash flow to net income ratio is slightly above 1, indicating that cash flow is aligned with reported losses. However, the negative growth in free cash flow and operating cash flow coverage ratio suggests ongoing cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	37.36M	35.00M	371.21M	436.00K	913.08M	543.00K
Gross Profit	-81.06M	-75.25M	240.96M	-109.81M	895.13M	-268.86M
EBITDA	-511.48M	-447.31M	-202.70M	-648.99M	391.48M	-345.25M
Net Income	-467.80M	-366.25M	-153.61M	-650.17M	377.66M	-348.87M
Balance Sheet
Total Assets	2.03B	2.24B	2.23B	2.24B	2.75B	1.83B
Cash, Cash Equivalents and Short-Term Investments	1.72B	1.90B	1.69B	1.82B	2.38B	1.69B
Total Debt	215.45M	223.69M	238.63M	244.02M	225.03M	61.43M
Total Liabilities	318.59M	309.95M	346.77M	367.58M	352.42M	163.73M
Stockholders Equity	1.71B	1.93B	1.88B	1.88B	2.40B	1.66B
Cash Flow
Free Cash Flow	-325.57M	-144.68M	-272.35M	-532.93M	457.27M	-256.72M
Operating Cash Flow	-324.77M	-142.77M	-260.38M	-495.74M	538.97M	-238.37M
Investing Cash Flow	-5.55M	-280.48M	374.65M	-258.65M	-1.04B	-541.17M
Financing Cash Flow	39.36M	331.98M	62.66M	38.59M	250.94M	1.02B

Crispr Therapeutics AG Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 52.74
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRSP, the sentiment is Neutral. The current price of 52.74 is below the 20-day moving average (MA) of 54.83, below the 50-day MA of 56.01, and above the 200-day MA of 45.15, indicating a neutral trend. The MACD of -1.00 indicates Positive momentum. The RSI at 43.39 is Neutral, neither overbought nor oversold. The STOCH value of 43.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CRSP.

Crispr Therapeutics AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	78 Outperform	$2.13B	12.10	27.58%	―	17.74%	59.96%
ARQT	58 Neutral	$1.84B	―	-57.33%	―	99.50%	65.91%
NTLA	55 Neutral	$1.22B	―	-56.95%	―	14.99%	14.42%
VERV	52 Neutral		―		―	271.44%	26.65%
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%
BEAM	50 Neutral	$1.65B	―	-41.94%	―	-82.90%	-155.64%
CRSP	46 Neutral	$4.79B	―	-25.34%	―	-81.18%	-69.19%

Crispr Therapeutics AG Corporate Events

CRISPR Therapeutics Updates on Cardiovascular Programs

On June 26, 2025, CRISPR Therapeutics AG announced updates on its in vivo cardiovascular disease programs, including new data for CTX310™, CTX320™, and CTX340™. CTX310™, targeting ANGPTL3, continues to show promising results in reducing triglycerides and low-density lipoprotein in its Phase 1 trial, with peak reductions of up to 82% and 86% respectively, without significant liver enzyme changes. CTX320™, targeting the LPA gene, is in an ongoing Phase 1 trial, with an update expected in the first half of 2026. Meanwhile, CTX340™, targeting angiotensinogen for refractory hypertension, is progressing through preclinical studies. These developments highlight CRISPR Therapeutics AG’s strategic advancements in addressing cardiovascular diseases, potentially impacting its market position and offering new treatment avenues for patients.

CRISPR Therapeutics AG Shareholders Approve Key Proposals

On June 5, 2025, CRISPR Therapeutics AG held its Annual General Meeting where shareholders approved several key proposals, including amendments to the company’s Articles of Association, financial statements for 2024, and the re-election of board members and auditors. These decisions, effective upon registration, are expected to strengthen the company’s governance and operational framework, potentially enhancing its strategic positioning in the biotechnology sector.